These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 9426721)

  • 21. Early diagnosis of prostate cancer in finasteride treated BPH patients.
    Tarle M; Kraus O; Trnski D; Reljic A; Ruzic B; Katusic J; Spajic B; Kusic Z
    Anticancer Res; 2003; 23(1B):693-6. PubMed ID: 12680169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359.
    Brawer MK; Lin DW; Williford WO; Jones K; Lepor H
    Prostate; 1999 Jun; 39(4):234-9. PubMed ID: 10344212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Terazosin vs finasteride for BPH.
    Zacks M
    J Fam Pract; 1996 Dec; 43(6):533. PubMed ID: 8969692
    [No Abstract]   [Full Text] [Related]  

  • 25. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
    Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ
    J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
    Keledjian K; Borkowski A; Kim G; Isaacs JT; Jacobs SC; Kyprianou N
    Prostate; 2001 Jul; 48(2):71-8. PubMed ID: 11433417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work?
    Kaplan SA; Olsson CA; Te AE
    J Urol; 1996 Jun; 155(6):1971-4. PubMed ID: 8618299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial.
    Roehrborn CG; Oesterling JE; Olson PJ; Padley RJ
    Urology; 1997 Oct; 50(4):556-61. PubMed ID: 9338731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
    Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PSA velocity in conservatively managed BPH: can it predict the need for BPH-related invasive therapy?
    Mochtar CA; Kiemeney LA; Laguna MP; Debruyne FM; de la Rosette JJ
    Prostate; 2006 Sep; 66(13):1407-12. PubMed ID: 16741919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
    Glassman DT; Chon JK; Borkowski A; Jacobs SC; Kyprianou N
    Prostate; 2001 Jan; 46(1):45-51. PubMed ID: 11170131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
    Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
    J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
    Agha AH; Roy JB; Culkin DJ; Lyon K
    Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.